Clopidogrel/acetylsalicylic acid regulatory update

EMA’s CHMP recommended approval of clopidogrel/acetylsalicylic acid from Teva to prevent atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid. Specifically, the fixed-dose combination of the platelet aggregation inhibitors would be indicated for use in ST-segment elevation acute myocardial infarction (MI) in medically treated patients and non-ST-segment elevation acute coronary syndrome (ACS), including in patients undergoing a stent placement following percutaneous coronary intervention (PCI). ...